Thromb Haemost 2019; 119(06): 906-915
DOI: 10.1055/s-0039-1683912
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

Binding of Coagulation Factor XIII Zymogen to Activated Platelet Subpopulations: Roles of Integrin αIIbβ3 and Fibrinogen

Yana N. Kotova*
1   Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
2   Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
,
Nadezhda A. Podoplelova*
1   Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
2   Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
,
Sergey I. Obydennyy
1   Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
2   Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
,
Elizaveta A. Kostanova
3   Emmanuel Institute of Biochemical Physics, Russian Academy of Science, Moscow, Russia
,
Alexander A. Ryabykh
2   Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
,
Aleksandra S. Demyanova
1   Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
,
Maria I. Biriukova
3   Emmanuel Institute of Biochemical Physics, Russian Academy of Science, Moscow, Russia
,
Mark A. Rosenfeld
3   Emmanuel Institute of Biochemical Physics, Russian Academy of Science, Moscow, Russia
,
Alexey V. Sokolov
4   Institute of Experimental Medicine, St. Petersburg, Russia
5   Chair of Fundamental Problems of Medicine, Saint Petersburg State University, St. Petersburg, Russia
,
Herve Chambost
6   INSERM, INRA, C2VN, Aix-Marseille Université, Marseille, France
,
Maria A. Kumskova
7   National Research Center for Hematology, Moscow, Russia
,
Fazoil I. Ataullakhanov
1   Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
2   Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
8   Faculty of Physics, Moscow State University, Moscow, Russia
,
Marie-Christine Alessi
5   Chair of Fundamental Problems of Medicine, Saint Petersburg State University, St. Petersburg, Russia
,
Mikhail A. Panteleev
1   Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
2   Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
8   Faculty of Physics, Moscow State University, Moscow, Russia
9   Faculty of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, Russia
› Author Affiliations
Funding This study was supported by the grant from the endowment foundation «Doctors, innovations, science for children», and by the Russian Foundation for Basic Research grants 16-04-00125, 17-00-00140, 17-04-01309, 18-34-20026 and 19-04-00615.
Further Information

Publication History

28 September 2018

04 February 2019

Publication Date:
01 April 2019 (online)

Abstract

Factor XIIIa (fXIIIa) is a transglutaminase that plays a crucial role in fibrin clot stabilization and regulation of fibrinolysis. It is known to bind to procoagulant platelets. In contrast, the zymogen fXIII interaction with platelets is not well characterized. We investigated the interaction of zymogen fXIII with activated platelet subpopulations. Confocal microscopy and flow cytometry using fluorescently labelled factors and antibodies. Phosphatidylserine (PS)-positive activated platelets bound 700 to 800 molecules/cell of fXIII at 100 nM, while both PS-negative activated platelets and resting platelets bound 200 to 400 molecules/cell. The binding was reversible, calcium-independent and linear within the fXIII concentration range of up to 1,000 nM. fXIII predominantly bound to the caps of procoagulant platelets and co-localized with fibrinogen. Exogenous fibrinogen promoted fXIII binding by activated PS-negative platelets; this effect was abolished by the integrin αIIbβ3 antagonist monafram. The fXIII binding was 1.5- to 3-fold decreased for platelets from four patients with grey platelet syndrome, and was variable for platelets from six patients with Glanzmann's thrombasthenia. Strong platelet stimulation, fibrinogen and αIIbβ3 play essential roles in fXIII binding, without any of them fXIII does not bind to platelets. The preferential binding in the cap-like structures might be important for increasing local fXIII concentration in platelet thrombi.

Authors' Contributions

Y.N.K., N.A.P., S.I.O., E.A.K., A.A.R., A.S.D., M.I.B., M.A.R. and A.V.S. performed experiments and analysed data. H.C., M.A.K. and M.C.A. recruited and characterized patients. M.C.A., F.I.A. and M.A.P. planned research and analysed the data. Y.N.K., N.A.P., M.C.A. and M.A.P. wrote the paper.


* These authors contributed equally to this work.


Supplementary Material

 
  • References

  • 1 Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 291-311
  • 2 Greenberg CS, Dobson JV, Miraglia CC. Regulation of plasma factor XIII binding to fibrin in vitro. Blood 1985; 66 (05) 1028-1034
  • 3 Muszbek L, Haramura G, Polgár J. Transformation of cellular factor XIII into an active zymogen transglutaminase in thrombin-stimulated platelets. Thromb Haemost 1995; 73 (04) 702-705
  • 4 Muszbek L, Polgár J, Boda Z. Platelet factor XIII becomes active without the release of activation peptide during platelet activation. Thromb Haemost 1993; 69 (03) 282-285
  • 5 Ariëns RAS, Lai T-S, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002; 100 (03) 743-754
  • 6 Aleman MM, Byrnes JR, Wang J-G. , et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014; 124 (08) 3590-3600
  • 7 Kasahara K, Kaneda M, Miki T. , et al. Clot retraction is mediated by factor XIII-dependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood 2013; 122 (19) 3340-3348
  • 8 Mitchell JL, Lionikiene AS, Fraser SR, Whyte CS, Booth NA, Mutch NJ. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood 2014; 124 (26) 3982-3990
  • 9 Mattheij NJA, Swieringa F, Mastenbroek TG. , et al. Coated platelets function in platelet-dependent fibrin formation via integrin αIIbβ3 and transglutaminase factor XIII. Haematologica 2016; 101 (04) 427-436
  • 10 Jobe SM, Leo L, Eastvold JS. , et al. Role of FcRgamma and factor XIIIA in coated platelet formation. Blood 2005; 106 (13) 4146-4151
  • 11 Kotova YN, Abaeva AA, Kolyadko VN. , et al. The role of transglutaminases in the regulation of phosphatidylserine-positive platelet formation. Biochem Suppl Ser A Membr Cell Biol 2015; 9: 229-235
  • 12 Podoplelova NA, Sveshnikova AN, Kotova YN. , et al. Coagulation factors bound to procoagulant platelets concentrate in cap structures to promote clotting. Blood 2016; 128 (13) 1745-1755
  • 13 Abaeva AA, Canault M, Kotova YN. , et al. Procoagulant platelets form an α-granule protein-covered “cap” on their surface that promotes their attachment to aggregates. J Biol Chem 2013; 288 (41) 29621-29632
  • 14 Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005; 3 (10) 2185-2192
  • 15 Heemskerk JWM, Mattheij NJA, Cosemans JMEM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11 (01) 2-16
  • 16 Greenberg CS, Shuman MA. Specific binding of blood coagulation factor XIIIa to thrombin-stimulated platelets. J Biol Chem 1984; 259 (23) 14721-14727
  • 17 Nagy Jr B, Simon Z, Bagoly Z, Muszbek L, Kappelmayer J. Binding of plasma factor XIII to thrombin-receptor activated human platelets. Thromb Haemost 2009; 102 (01) 83-89
  • 18 Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood 1994; 83 (04) 1006-1016
  • 19 Kreager JA, Devine DV, Greenberg CS. Cytofluorometric identification of plasmin-sensitive factor XIIIa binding to platelets. Thromb Haemost 1988; 60 (01) 88-93
  • 20 Nechipurenko DY, Receveur N, Yakimenko AO. , et al. Clot contraction drives the translocation of procoagulant platelets to thrombus surface. Arterioscler Thromb Vasc Biol 2019; 39 (01) 37-47
  • 21 Mazurov AV, Pevzner DV, Antonova OA. , et al. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty. Platelets 2002; 13 (08) 465-477
  • 22 Zakharova NV, Artemenko EO, Podoplelova NA. , et al. Platelet surface-associated activation and secretion-mediated inhibition of coagulation factor XII. PLoS One 2015; 10 (02) e0116665
  • 23 Zakharova N, Podoplelova NA, Demina IA. Platelets from patients with hereditary dense-granule disorders support surface-associated factor XII activation. Arch Blood Transfus Disord 2017; 1 (01) ABTD.000502
  • 24 Sokolov AV, Kostevich VA, Romanico DN. , et al. Two-stage method for purification of ceruloplasmin based on its interaction with neomycin. Biochem SP MAIK Nauka/Interperiodica 2012; 77: 631-638
  • 25 Sokolov AV, Acquasaliente L, Kostevich VA. , et al. Thrombin inhibits the anti-myeloperoxidase and ferroxidase functions of ceruloplasmin: relevance in rheumatoid arthritis. Free Radic Biol Med 2015; 86: 279-294
  • 26 Vasilyeva A, Yurina L, Indeykina M. , et al. Oxidation-induced modifications of the catalytic subunits of plasma fibrin-stabilizing factor at the different stages of its activation identified by mass spectrometry. Biochim Biophys Acta Proteins Proteomics 2018; 1866 (08) 875-884
  • 27 Podoplelova NA, Sveshnikova AN, Kurasawa JH. , et al. Hysteresis-like binding of coagulation factors X/Xa to procoagulant activated platelets and phospholipids results from multistep association and membrane-dependent multimerization. Biochim Biophys Acta 2016; 1858 (06) 1216-1227
  • 28 Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. J Biol Chem 2004; 279 (29) 30697-30706
  • 29 Dardik R, Shenkman B, Tamarin I. , et al. Factor XIII mediates adhesion of platelets to endothelial cells through alpha(v)beta(3) and glycoprotein IIb/IIIa integrins. Thromb Res 2002; 105 (04) 317-323
  • 30 Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry 1996; 35 (32) 10448-10453
  • 31 Mattheij NJA, Gilio K, van Kruchten R. , et al. Dual mechanism of integrin αIIbβ3 closure in procoagulant platelets. J Biol Chem 2013; 288 (19) 13325-13336
  • 32 Yakimenko AO, Verholomova FY, Kotova YN, Ataullakhanov FI, Panteleev MA. Identification of different proaggregatory abilities of activated platelet subpopulations. Biophys J 2012; 102 (10) 2261-2269
  • 33 Lewis JC, Hantgan RR, Stevenson SC. , et al. Fibrinogen and glycoprotein IIb/IIIa localization during platelet adhesion. Localization to the granulomere and at sites of platelet interaction. Am J Pathol 1990; 136 (01) 239-252
  • 34 Kieffer N, Guichard J, Breton-Gorius J. Dynamic redistribution of major platelet surface receptors after contact-induced platelet activation and spreading. An immunoelectron microscopy study. Am J Pathol 1992; 140 (01) 57-73
  • 35 Greenberg CS, Shuman MA. The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. J Biol Chem 1982; 257 (11) 6096-6101
  • 36 Byrnes JR, Wilson C, Boutelle AM. , et al. The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits. Blood 2016; 128 (15) 1969-1978